欧康维视生物-B(01477)：治疗术后炎症适应症新药OT-502于中国的III期临床试验达到主要终点

智通财经04-15

智通财经APP讯，欧康维视生物-B(01477)发布公告，一款治疗术后炎症适应症的新药OT-502(DEXYCU®，地塞米松植入剂)已成功达到其III期临床试验的预期主要疗效终点，即第8天时，地塞米松植入剂的治疗组中眼前房细胞清除(ACC 0级)的受试者比例显著高于安慰剂组，证明本品在控制白内障术后炎症方面安全有效。公司预期将于近期向中国国家药品监督管理局药品审评中心递交OT-502的新药申请。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2427012972?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-15 12:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2427012972","market":"us","top_or_hot":-1,"title":"欧康维视生物-B(01477)：治疗术后炎症适应症新药OT-502于中国的III期临床试验达到主要终点","media":"智通财经","content":"<div>\n<p>智通财经APP讯，欧康维视生物-B(01477)发布公告，一款治疗术后炎症适应症的新药OT-502(DEXYCU®，地塞米松植入剂)已成功达到其III期临床试验的预期主要疗效终点，即第8天时，地塞米松植入剂的治疗组中眼前房细胞清除(ACC 0级)的受试者比例显著高于安慰剂组，证明本品在控制白内障术后炎症方面安全有效。公司预期将于近期向中国国家药品监督管理局药品审评中心递交OT-502的新药申请。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1102390.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>欧康维视生物-B(01477)：治疗术后炎症适应症新药OT-502于中国的III期临床试验达到主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n欧康维视生物-B(01477)：治疗术后炎症适应症新药OT-502于中国的III期临床试验达到主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-15 12:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1102390.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，欧康维视生物-B(01477)发布公告，一款治疗术后炎症适应症的新药OT-502(DEXYCU®，地塞米松植入剂)已成功达到其III期临床试验的预期主要疗效终点，即第8天时，地塞米松植入剂的治疗组中眼前房细胞清除(ACC 0级)的受试者比例显著高于安慰剂组，证明本品在控制白内障术后炎症方面安全有效。公司预期将于近期向中国国家药品监督管理局药品审评中心递交OT-502的新药申请。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1102390.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1102390.html","article_id":"2427012972","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427012972","pubTimestamp":1713154664,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，欧康维视生物-B 发布公告，一款治疗术后炎症适应症的新药OT-502已成功达到其III期临床试验的预期主要疗效终点，即第8天时，地塞米松植入剂的治疗组中眼前房细胞清除的受试者比例显著高于安慰剂组，证明本品在控制白内障术后炎症方面安全有效。公司预期将于近期向中国国家药品监督管理局药品审评中心递交OT-502的新药申请。集团正在开发 OT-502，作为中国白内障手术相关术后炎症的潜在同类首创疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4134":"信息科技咨询与其它服务","01477":"欧康维视生物-B","BK1191":"制药","BK1141":"生命科学工具和服务","BK1574":"生物医药B类股","BK1576":"医药外包概念","III":"信息服务","03347":"泰格医药","BK1583":"高瓴概念"},"translate_title":"Okuvision Bio-B (01477): Phase III clinical trial of OT-502, a new drug for the treatment of postoperative inflammation indications, in China reached the primary endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"03347":1,"III":1},"content_text":"智通财经APP讯，欧康维视生物-B(01477)发布公告，一款治疗术后炎症适应症的新药OT-502(DEXYCU®，地塞米松植入剂)已成功达到其III期临床试验的预期主要疗效终点，即第8天时，地塞米松植入剂的治疗组中眼前房细胞清除(ACC 0级)的受试者比例显著高于安慰剂组，证明本品在控制白内障术后炎症方面安全有效。公司预期将于近期向中国国家药品监督管理局药品审评中心递交OT-502的新药申请。OT-502(地塞米松植入剂)是地塞米松(一种皮质类固醇)的单剂量缓释药物，用于治疗白内障术后炎症。迄今为止，OT-502是首种也是唯一一种获美国食品药品监督管理局批准用于术后炎症的单剂量缓释型后房内类固醇。集团正在开发 OT-502，作为中国白内障手术相关术后炎症的潜在同类首创疗法。OT-502的III期临床试验为随机、双盲、安慰剂对照、平行组、多中心临床及药代动力学研究，以评估9%地塞米松植入剂治疗白内障术后炎症的有效性及安全性，已于2023年11月于中国完成患者入组。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427012972"}